Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.61 |
| ▸ | GAK | O14976 | 2/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.57 |
| ▸ | FBP1 | P09467 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12743451 | 0.89 | EGFR (0.79) | EGFRGAKERBB2ERBB4HDAC3 | |
| Hydrochloric Acid SCHEMBL1446356 | 0.88 | EGFR (0.78) | EGFRGAKERBB2ERBB4HDAC3 | |
| SCHEMBL5567887 | 0.88 | EGFR (0.61) | EGFRGAKERBB2FBP1ERBB4 | |
| SCHEMBL29623603 | 0.80 | EGFR (0.75) | EGFRGAKERBB2FBP1LCK | |
| SCHEMBL185543 | 0.80 | EGFR (0.75) | EGFRGAKERBB2FBP1LCK | |
| SCHEMBL29087931 | 0.80 | EGFR (0.64) | EGFRGAKERBB2FBP1EPHA2 | |
| SCHEMBL30638099 | 0.80 | EGFR (0.64) | EGFRGAKERBB2FBP1EPHA2 | |
| SCHEMBL1446486 | 0.80 | EGFR (0.79) | EGFRGAKERBB2ERBB4HDAC3 | |
| Hydrochloric Acid SCHEMBL1446303 | 0.80 | EGFR (0.74) | EGFRGAKERBB2FBP1LCK | |
| Hydrochloric Acid SCHEMBL4085852 | 0.80 | EGFR (0.74) | EGFRGAKERBB2FBP1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | EGFR 15/4885GAK 289/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.